EP Patent

EP3300601A1 — Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Assigned to Rotalec IP Holdings LLC · Expires 2018-04-04 · 8y expired

What this patent protects

Provided herein is a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, non-antagonistic molar ratio encapsulated in liposomes for use in the treatment of patients with hematologic disorders.

USPTO Abstract

Provided herein is a pharmaceutical composition comprising cytarabine and daunorubicin at a fixed, non-antagonistic molar ratio encapsulated in liposomes for use in the treatment of patients with hematologic disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3300601A1
Jurisdiction
EP
Classification
—
Expires
2018-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Rotalec IP Holdings LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.